top of page
SERNA BIO
MAPPING THE DRUGGABLE TRANSCRIPTOME
An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins.
While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed.
At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our Discovery Platform powers our first-in-class small molecule programs targeted at classically undruggable proteins and non-coding RNA targets, targeting both human and non-human biology.
WHAT WE ARE UP TO
At Serna Bio, we are always pushing the frontier of what is known: we are building the world's first map of the druggable transcriptome.
We are proud of our achievements and love sharing our knowledge with community. Our news section includes information about our latest publications, events and business analysis - give us a shout if you can’t find the information you’re looking for.
Read our blog, our thoughts and learnings from building a company in this nascent space, including a competitive landscape covering all RNA-small molecule targeting companies
bottom of page